PDBrown
@PDBrownOnc
Followers
2K
Following
9K
Media
332
Statuses
1K
Husband, dad, grandfather, lifelong learner, amateur brewer, outdoor enthusiast, Professor Radiation Oncology #Brainmet #radiosurgery #radonc
Rochester, MN
Joined May 2012
Kudos Dr. Gal @larosa_rosa3 @OdiaYazmin @Rrkotecha & @MiamiCancerInst colleagues.Pertinent ongoing trial NRG BN014 Proton CSI vs involved field RT for Breast CA or NSCLC LMD .(RADIATE-LM).
0
1
6
Leptomeningeal Disease (LMD).· 38 patients LMD proton CSI 30Gy/10.· 42% Gr3 lymphopenia, 4% Gr4 lymph/neutropenia.· Median OS 10 mos .#mdpicancers via @Cancers_MDPI
3
11
44
Interesting study @Bardii47 @SalemTosMD & colleagues. In this particular case treated SRS 30/5 (priority CTV>Optics>PTV), 3 mos after SRS excellent imaging response and partial improvement in DI.
0
0
1
Pit Met.What is chance DI improves w/SRS?.40% according to this study.· 79 pit mets SRS (single frac in 90%).· 77% CN dysf & 0% anterior pit function improved.· 92% LC
1
2
12
Congrats Dr. Crompton @shelby_kern17 @savora @DoctorQMd @TerryBurnsLab @UgurSenerMD @PorterAlyx @n_laack @wgbreen @DanTrifMD & @MayoClinic colleagues.TTF utilization 20% from 2019-2023.@MayoRadOnc.
0
0
4
Is there real world benefit Tumor Treating Fields in GBM?.Yes, according to this study 393 GBM treated w/ RT + TMZ.· 2-year OS w/TTF 58% vs 41% without.· MVA TTF use ↑↑ OS (p=0.038).
1
7
37
(Older) Prospective trial Boswellia University of Tübingen.· 11 Gliomas, 1 Brain Met w/progressive edema.· 29% had ↓↓tumor edema.· 60% had ↓↓treatment-related leukoencephalopathy
2
14
37
@Mat_Guc @LotteWilke Similar results Kobe City Phase 2 Dose Escalation 40-45 Gy/5 to Gross DZ.· 28 spine mets.· 1 & 2 Yr LC 100% + 95%.· Vert Comp Fx 1 & 2 Yr 4% + 16%.
1
0
3
Prospective study dose intensified SBRT vertebral oligomets.· Excellent local control.
1
11
33
Review Radiotherapy for Dupuytren Contracture.Helpful clinical FU worksheet provided (sample below).
2
13
45
Kudos Dr. Kumar @Lucas_Carlstrom @RaminMorshedMD @n_laack @graffeo @MichaelJLinkMD @MayoClinic colleagues.4% Symptomatic perilesional edema & 4% cranial neuropathies. @MayoRadOnc.
0
0
3
25-year Cohort Study SRS sporadic meningioma.· 653 tumors SRS.· Median volume & margin dose 4.5 cc & 15 Gy.· In-field & marginal progression 1.1% & 0.3%.· 10 Yr PFS 99%.
2
9
40
Kudos Dr. Mercier & ROBOMET team.Local Control (primary reason for SBRT over 3DRT) best assessed by CCTG SC.24 @MayoRadOnc.
0
0
3
Randomized Trial 8 Gy vs. SBRT 20Gy Bone Met.· “Negative trial” but CR rates tended to favor SBRT.· No increase pain flare w/SBRT.
3
9
25
RT @OncLive: Thanks to @AyalAizer of @DanaFarber for stopping by to discuss a phase 3 trial comparing stereotactic radiation vs hippocampal….
0
1
0
Congrats @AyalAizer @XRTanguturi @DanielCagney @DhaasKogan @NayanLamba @RifRahmanMD & colleagues for this practice changing trial.Abstract #2011.@MayoRadOnc.
0
0
5